Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$331M |
| 2 |
Aon
AON
|
+$321M |
| 3 |
WUBA
58.com Inc
WUBA
|
+$256M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$217M |
| 5 |
TIF
Tiffany & Co.
TIF
|
+$191M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.65B |
| 2 |
Cigna
CI
|
+$142M |
| 3 |
Fidelity National Information Services
FIS
|
+$135M |
| 4 |
General Dynamics
GD
|
+$132M |
| 5 |
Wabtec
WAB
|
+$113M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.19% |
| 2 | Communication Services | 20.54% |
| 3 | Technology | 10.42% |
| 4 | Financials | 7.52% |
| 5 | Consumer Discretionary | 4.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TIF
26
DELISTED
Tiffany & Co.
TIF
| $186M | 1.49% |
+1,527,698
| New | +$191M |
|
27
Iovance Biotherapeutics
IOVA
$3.76B
| $179M | 1.44% |
6,537,500
+787,500
| +14% | +$25.9M |
|
28
New York Times
NYT
$10.6B
| $174M | 1.39% |
+4,137,542
| New | +$150M |
|
|
29
General Dynamics
GD
$104B
| $172M | 1.38% |
1,151,481
-932,200
| -45% | -$132M |
|
30
Ascendis Pharma A/S
ASND
$16.6B
| $169M | 1.35% |
1,140,000
-236,349
| -17% | -$32.5M |
|
|
BMY.RT
31
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $158M | 1.27% |
44,200,000
+9,000,000
| +26% | +$32.5M |
|
32
Blackstone
BX
$108B
| $157M | 1.26% |
2,768,319
+2,365,508
| +587% | +$125M |
|
33
Alnylam Pharmaceuticals
ALNY
$31.6B
| $156M | 1.24% |
1,050,000
-450,000
| -30% | -$60.7M |
|
34
Qiagen
QGEN
$9.1B
| $123M | 0.99% |
2,716,943
-75,431
| -3% | -$3.38M |
|
|
WMGI
35
DELISTED
Wright Medical Group Inc
WMGI
| $122M | 0.98% |
4,100,000
+1,825,000
| +80% | +$53.4M |
|
36
Fate Therapeutics
FATE
$279M
| $120M | 0.96% |
3,500,000
+500,000
| +17% | +$14.9M |
|
|
PLYA
37
DELISTED
Playa Hotels & Resorts
PLYA
| $111M | 0.89% |
30,606,930
| – | – |
|
38
TransUnion
TRU
$16.2B
| $104M | 0.83% |
1,192,747
-831,140
| -41% | -$66.3M |
|
|
CZR
39
DELISTED
Caesars Entertainment Corporation
CZR
| $97.2M | 0.78% |
+8,015,000
| New | +$81M |
|
|
40
Cigna
CI
$73.3B
| $93.8M | 0.75% |
500,000
-750,000
| -60% | -$142M |
|
41
Enanta Pharmaceuticals
ENTA
$392M
| $87.9M | 0.7% |
1,750,000
| – | – |
|
|
MYOK
42
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $84.5M | 0.68% |
875,000
+445,000
| +103% | +$37.1M |
|
43
Sarepta Therapeutics
SRPT
$1.98B
| $84.2M | 0.67% |
525,000
+175,000
| +50% | +$23.8M |
|
44
New Oriental
EDU
$8.88B
| $82.2M | 0.66% |
+631,000
| New | +$76.9M |
|
|
MRTX
45
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $74.2M | 0.59% |
650,000
+50,000
| +8% | +$4.85M |
|
|
APLS
46
DELISTED
Apellis Pharmaceuticals
APLS
| $73.5M | 0.59% |
2,250,000
+250,000
| +13% | +$8.03M |
|
|
BRMK
47
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $67.9M | 0.54% |
7,170,213
| – | – |
|
48
Agios Pharmaceuticals
AGIO
$1.98B
| $66.8M | 0.54% |
1,250,000
| – | – |
|
|
KYNB
49
Kyntra Bio
KYNB
$30.4M
| $65.9M | 0.53% |
65,000
+1,013
| +2% | +$941K |
|
|
KRTX
50
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $64.1M | 0.51% |
575,000
+7,953
| +1% | +$691K |
|
Similar funds
Thomas Steyer's Q2 2020 Portfolio in Review
As of Q2 2020, Thomas Steyer held 137 positions worth $12.5B, up 7.2% from $11.7B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Thomas Steyer withdrew a net $1.62B in Q2 2020, closing 18 positions and reducing 37 holdings. Its most notable exit was Allergan plc, an estimated $1.65B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 52% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Thomas Steyer opened a new position in T-Mobile US worth $360M.
- Thomas Steyer's largest Q2 2020 buy was T-Mobile US: 3,457,631 shares worth $360M.
- Thomas Steyer added most to Blackstone in Q2 2020, an estimated $125M increase.
- Thomas Steyer's biggest Q2 2020 reduction was Cigna, cutting an estimated $142M.
- Thomas Steyer fully exited Allergan plc in Q2 2020, selling an estimated $1.65B.
- Thomas Steyer's ten largest holdings make up 33% of its $12.5B portfolio in Q2 2020.
- Thomas Steyer opened 32 new positions and closed 18 in Q2 2020.
- Thomas Steyer's portfolio value rose 7.2% quarter-over-quarter to $12.5B.
Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.